The Department of Cardiology is committed to advancing the frontier of medical knowledge through innovative clinical research. Most of the treatment paradigms in cardiology are based on clinical trials that exclude cancer patients. We are in the unique position to evaluate diagnostic or treatment strategies that affect our patient population.
- A MultiCenter Study in Patients Undergoing AnthRacycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
- A Study to Evaluate Efficacy and Safety of Apixaban In Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation (ARISTOTLE) Protocol 2007-0049
- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS Study
- Registry of AT/AF Episodes in the CRM Device Population: RATE Registry Protocol 2006-0916
- Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers Protocol 2006-0921
- Cardiomyopathy Tissue Bank in a Cancer Population Protocol ID02-359
- Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism (RE-SONATE)